Colorectal carcinoma metastases: Detection with In-111-labeled monoclonal antibody CCR 086

H. H. Abdel-Nabi; G. Levine; L. M. Lamki; J. L. Murray; W. N. Tauxe; A. N. Shah; Y. Z. Patt; R. J. Doerr; H. A. Klein; J. Gona; M. J. Rosenblum; M. J. Unger; L. M. Smith; S. A. Schweighardt; E. B. Merchant

doi:10.1148/radiology.176.1.2353080

Colorectal carcinoma metastases: Detection with In-111-labeled monoclonal antibody CCR 086

H. H. Abdel-Nabi^*, G. Levine, L. M. Lamki, J. L. Murray, W. N. Tauxe, A. N. Shah, Y. Z. Patt, R. J. Doerr, H. A. Klein, J. Gona, M. J. Rosenblum, M. J. Unger, L. M. Smith, S. A. Schweighardt, E. B. Merchant

^*Corresponding author for this work

Radiology & Molecular Imaging

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

A phase I/II clinical trial with indium-111-labeled antimucin murine monoclonal antibody (MoAb) CCR 086 was conducted. Seventeen patients with histologically proved colorectal carcinoma and known metastatic disease underwent external scintigraphy after administration of 5.5 mCi (203.5 MBq) of In-111 CCR 086 at doses of 5 and 20 mg. Of 25 known lesions, 17 were detected (sensitivity, 68%). The smallest detected lesion in the lung was 1 cm and in the liver was 1.5 cm. The serum half-life of In-111-labeled CCR 086 MoAb was approximately 64 hours. The formation of human antimouse antibody (HAMA) was detected in the serum of four of five patients who received 20 mg of MoAb. No HAMAs were detected in four patients receiving 5 mg of MoAb. No side effects were encountered. Because of effective detection of liver and lung metastases with lower doses (5-20 mg) of CCR 086 conjugated with In-111, further investigations are warranted to assess clinical and therapeutic potentials of CCR 086 in the management of colorectal cancer.

Original language	English
Pages (from-to)	117-122
Number of pages	6
Journal	Radiology
Volume	176
Issue number	1
DOIs	https://doi.org/10.1148/radiology.176.1.2353080
Publication status	Published - 1990

Keywords

Colon, neoplasms
indium, radioactive
liver neoplasms, secondary
liver, radionuclide studies
lung neoplasms, secondary
lung, radionuclide studies
monoclonal antibodies
rectum, neoplasms

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1148/radiology.176.1.2353080

Cite this

Abdel-Nabi, H. H., Levine, G., Lamki, L. M., Murray, J. L., Tauxe, W. N., Shah, A. N., Patt, Y. Z., Doerr, R. J., Klein, H. A., Gona, J., Rosenblum, M. J., Unger, M. J., Smith, L. M., Schweighardt, S. A., & Merchant, E. B. (1990). Colorectal carcinoma metastases: Detection with In-111-labeled monoclonal antibody CCR 086. Radiology, 176(1), 117-122. https://doi.org/10.1148/radiology.176.1.2353080

@article{84ebf984b2144ba4a134c8caa25ef588,

title = "Colorectal carcinoma metastases: Detection with In-111-labeled monoclonal antibody CCR 086",

abstract = "A phase I/II clinical trial with indium-111-labeled antimucin murine monoclonal antibody (MoAb) CCR 086 was conducted. Seventeen patients with histologically proved colorectal carcinoma and known metastatic disease underwent external scintigraphy after administration of 5.5 mCi (203.5 MBq) of In-111 CCR 086 at doses of 5 and 20 mg. Of 25 known lesions, 17 were detected (sensitivity, 68%). The smallest detected lesion in the lung was 1 cm and in the liver was 1.5 cm. The serum half-life of In-111-labeled CCR 086 MoAb was approximately 64 hours. The formation of human antimouse antibody (HAMA) was detected in the serum of four of five patients who received 20 mg of MoAb. No HAMAs were detected in four patients receiving 5 mg of MoAb. No side effects were encountered. Because of effective detection of liver and lung metastases with lower doses (5-20 mg) of CCR 086 conjugated with In-111, further investigations are warranted to assess clinical and therapeutic potentials of CCR 086 in the management of colorectal cancer.",

keywords = "Colon, neoplasms, indium, radioactive, liver neoplasms, secondary, liver, radionuclide studies, lung neoplasms, secondary, lung, radionuclide studies, monoclonal antibodies, rectum, neoplasms",

author = "Abdel-Nabi, {H. H.} and G. Levine and Lamki, {L. M.} and Murray, {J. L.} and Tauxe, {W. N.} and Shah, {A. N.} and Patt, {Y. Z.} and Doerr, {R. J.} and Klein, {H. A.} and J. Gona and Rosenblum, {M. J.} and Unger, {M. J.} and Smith, {L. M.} and Schweighardt, {S. A.} and Merchant, {E. B.}",

year = "1990",

doi = "10.1148/radiology.176.1.2353080",

language = "English",

volume = "176",

pages = "117--122",

journal = "Radiology",

issn = "0033-8419",

publisher = "Radiological Society of North America Inc.",

number = "1",

}

TY - JOUR

T1 - Colorectal carcinoma metastases

T2 - Detection with In-111-labeled monoclonal antibody CCR 086

AU - Abdel-Nabi, H. H.

AU - Levine, G.

AU - Lamki, L. M.

AU - Murray, J. L.

AU - Tauxe, W. N.

AU - Shah, A. N.

AU - Patt, Y. Z.

AU - Doerr, R. J.

AU - Klein, H. A.

AU - Gona, J.

AU - Rosenblum, M. J.

AU - Unger, M. J.

AU - Smith, L. M.

AU - Schweighardt, S. A.

AU - Merchant, E. B.

PY - 1990

Y1 - 1990

N2 - A phase I/II clinical trial with indium-111-labeled antimucin murine monoclonal antibody (MoAb) CCR 086 was conducted. Seventeen patients with histologically proved colorectal carcinoma and known metastatic disease underwent external scintigraphy after administration of 5.5 mCi (203.5 MBq) of In-111 CCR 086 at doses of 5 and 20 mg. Of 25 known lesions, 17 were detected (sensitivity, 68%). The smallest detected lesion in the lung was 1 cm and in the liver was 1.5 cm. The serum half-life of In-111-labeled CCR 086 MoAb was approximately 64 hours. The formation of human antimouse antibody (HAMA) was detected in the serum of four of five patients who received 20 mg of MoAb. No HAMAs were detected in four patients receiving 5 mg of MoAb. No side effects were encountered. Because of effective detection of liver and lung metastases with lower doses (5-20 mg) of CCR 086 conjugated with In-111, further investigations are warranted to assess clinical and therapeutic potentials of CCR 086 in the management of colorectal cancer.

AB - A phase I/II clinical trial with indium-111-labeled antimucin murine monoclonal antibody (MoAb) CCR 086 was conducted. Seventeen patients with histologically proved colorectal carcinoma and known metastatic disease underwent external scintigraphy after administration of 5.5 mCi (203.5 MBq) of In-111 CCR 086 at doses of 5 and 20 mg. Of 25 known lesions, 17 were detected (sensitivity, 68%). The smallest detected lesion in the lung was 1 cm and in the liver was 1.5 cm. The serum half-life of In-111-labeled CCR 086 MoAb was approximately 64 hours. The formation of human antimouse antibody (HAMA) was detected in the serum of four of five patients who received 20 mg of MoAb. No HAMAs were detected in four patients receiving 5 mg of MoAb. No side effects were encountered. Because of effective detection of liver and lung metastases with lower doses (5-20 mg) of CCR 086 conjugated with In-111, further investigations are warranted to assess clinical and therapeutic potentials of CCR 086 in the management of colorectal cancer.

KW - Colon, neoplasms

KW - indium, radioactive

KW - liver neoplasms, secondary

KW - liver, radionuclide studies

KW - lung neoplasms, secondary

KW - lung, radionuclide studies

KW - monoclonal antibodies

KW - rectum, neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0025358768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025358768&partnerID=8YFLogxK

U2 - 10.1148/radiology.176.1.2353080

DO - 10.1148/radiology.176.1.2353080

M3 - Article

C2 - 2353080

AN - SCOPUS:0025358768

SN - 0033-8419

VL - 176

SP - 117

EP - 122

JO - Radiology

JF - Radiology

IS - 1

ER -

Colorectal carcinoma metastases: Detection with In-111-labeled monoclonal antibody CCR 086

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this